We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Ask ADVFN Intelligence (AI)
Topline Data from Phase 2b clinical trial of OST-HER2 in Osteosarcoma expected to be released in December 2024 OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a...
OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, Chief...
OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, is pleased to invite investors to...
Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.13 | 60.4278074866 | 1.87 | 4.77 | 1.8248 | 130364 | 3.70259323 | CS |
| 4 | 0.63 | 26.582278481 | 2.37 | 4.77 | 1.58 | 56377 | 3.0135425 | CS |
| 12 | -0.5 | -14.2857142857 | 3.5 | 4.77 | 1.58 | 39769 | 2.97799549 | CS |
| 26 | -1 | -25 | 4 | 4.9 | 1.58 | 122391 | 3.656465 | CS |
| 52 | -1 | -25 | 4 | 4.9 | 1.58 | 122391 | 3.656465 | CS |
| 156 | -1 | -25 | 4 | 4.9 | 1.58 | 122391 | 3.656465 | CS |
| 260 | -1 | -25 | 4 | 4.9 | 1.58 | 122391 | 3.656465 | CS |
| Symbol | Price | Vol. |
|---|---|---|
| MSTZT Rex 2X Inverse MSTR Daily Target ETF | US$ 0.841198 (-7.56%) | 946.17M |
| SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 30.70 (7.87%) | 102.19M |
| NVDQT Rex 2X Inverse NVIDIA Daily Target ETF | US$ 3.535 (4.59%) | 65.43M |
| SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 5.835 (0.43%) | 52.08M |
| SENSSenseonics Holdings Inc | US$ 0.46 (6.70%) | 51.08M |
JPetroInc
3 months ago
JPetroInc
3 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
